Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI ® (maralixibat) oral solution and tablet formulation for the ...

Mirum Pharma receives Health Canada authorization for maralixibat to treat cholestatic pruritus in patients with Alagille syndrome: Toronto Saturday, February 7, 2026, 15:00 Hrs [ ...

Obeticholic acid, which is marketed as Ocaliva as a treatment for a type of liver disease known as primary biliary cholangitis, has come under scrutiny recently. Although the US Food and Drug ...

Peking University, October 30, 2024: Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by ...

Approximately a quarter of individuals with primary sclerosing cholangitis experience moderate-severe pruritus.

Chronic itch has often been dismissed as a minor skin complaint; however, experts view it as a warning sign of deeper disease ...

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...